Tom Thomas
InvestorPrincipal at Newpath Partners
Boston, Massachusetts
Writes $500K β $40M checks Β· typically $15M
About
Tom Thomas is an investor at Newpath Partners and serves as a board director at CREATE Medicines. He has held positions at RA Capital Management focusing on oncology investments and co-founded Flagship Labs 89, where he served as head of translational biology. His background includes cancer biology research with expertise in patient-derived cell models, organoid systems, and cancer metabolomics.
Experience
- CREATE MedicinesBoard Directorcurrent2026 β present
- Cleveland ClinicExternal Advisory Councilcurrent2026 β present
- Newpath PartnersInvestor, Principalcurrent2024 β present
- UCLA Technology Development GroupTherapeutics Advisory Panel, UCLA Innovation Fundcurrent2025 β present
- Magnet BiomedicineBoard Observercurrent2024 β present
- Exo TherapeuticsBoard Directorcurrent2024 β present
- Kisbee TherapeuticsBoard Observer2024 β 2025
- Sera Medicines, LLCFounding Team2023 β 2024
- RA Capital Management, L.P.Healthcare Associate2022 β 2024Boston, Massachusetts, United States
- Prologue MedicinesFounding Team2021 β 2022
- Flagship PioneeringAssociate2020 β 2022Cambridge, Massachusetts, United States
- Flagship PioneeringFellow2020Cambridge, Massachusetts, United States
- Emmanuel College (Boston)Adjunct Faculty of Biology2018 β 2020Greater Boston Area
- Harvard Medical SchoolResearch Fellow2017 β 2020Boston, Massachusetts, United States
- Cedars-SinaiPh.D Candidate, Cancer Biology2013 β 2017
- University of California, Los AngelesResearch Associate2008 β 2011Los Angeles, California, United States
- Scripps ResearchResearch Intern2005 β 2006
Education
- Harvard Medical SchoolPostdoctoral Fellowship, Molecular Pathology & Oncology
- Cedars-Sinai Medical CenterPh.D., Biomedical Science and Translational Medicine
- UCLAB.S., Physiological Sciences
Skills & more
Board GovernanceCorporate StrategyProject Portfolio ManagementStart-up VenturesStart-up LeadershipEarly Stage InvestmentNew Venture DevelopmentCell Culture12Molecular Biology9Genetics4Clinical Research7Research5
+11 more
BiochemistryCancer ResearchCancerTumor ImmunologyStem Cell ResearchCancer Stem CellsTissue CultureMetabolismMicrosoft OfficeHealthcare InvestingCell BiologyLanguages English Β· Malayalam Β· Spanish
- Health Care Economics β Harvard Business School
- Healthcare Innovation & Commercialization β Harvard Medical School
From Tom's professional profile.
Colleagues at Newpath Partners
Frequently asked questions
- Where does Tom Thomas work?
- Tom Thomas is Principal at Newpath Partners.
- What check size does Tom Thomas write?
- Tom Thomas typically writes checks of $500K β $40M.
Same school
Also attended Harvard Medical School135
Niko BonatsosInvestment Team at General CatalystAnthony PhilippakisInvestor at GV (Google Ventures)Ben RobbinsInvestor at GV (Google Ventures)David ReshefInvestor at GV (Google Ventures)Krishna YeshwantInvestor at GV (Google Ventures)Morgan CheathamPartner and Head of Healthcare and Life Sciences at Breyer Capital
+ 129 more
Also attended UCLA471
Ben HorowitzCo-founder & General Partner at Andreessen HorowitzRon ConwayFounder of SV AngelKirsten GreenFounder and Managing Partner at Forerunner VenturesPaul FieldingFinance & Operations at General CatalystMelody MaExecutive Assistant and Lead Receptionist at Trinity VenturesGizem CakilInvestor at OpenView Venture Partners
+ 465 more
Shared employers
Also worked at Exo Therapeutics2
Also worked at Flagship Pioneering74
Anika GuptaInvestor at GV (Google Ventures)Noubar AfeyanInvestor at Flagship PioneeringSamir KaulInvestor at Khosla VenturesCassidy BlundellPartner at Mission BiocapitalDavid KoleskyPrincipal at MPM BioImpactDiana BernsteinDirector at Northpond Ventures
+ 68 more
Also worked at Emmanuel College (Boston)2
Also worked at Harvard Medical School162
Logan HilleLife Sciences Analyst at CincyTechAnkit GuptaGeneral Partner at Y CombinatorDavid MollerInvestor at Third Rock VenturesJulie YangInvestor at Third Rock VenturesTracy WilliamsInvestor at Third Rock VenturesSamuel ArbesmanVenture Partner at Lux Capital
+ 156 more










.png)





















